DÜSSELDORF, Germany, Feb. 14, 2013 /CNW/ -
Revenues rise by 11.4% (9.8% at constant exchange rates) to EUR 1,219m
Adjusted operating margin (adjusted EBITDA margin) amounts to 19.4%
Net income grows by 22.2% to EUR 66.5m
Proposed dividend of EUR 0.65 per share
Presence in the emerging markets most recently expanded through two
acquisitions in India
Gerresheimer AG, one of the leading worldwide partners of the pharma and
healthcare industry, has closed the 2012 financial year with
significant growth in revenues and profits. "We achieved all our
targets in 2012. We recorded another year of strong growth in our
business activities with the pharmaceutical sector, which once again
proved to be relatively immune to cyclical effects. We are investing
heavily in expanding our production capacity for medical devices such
as prefilled glass syringes, insulin pens and inhalers. We are also
focusing on the fast-growing emerging markets, especially in China,
Brazil and India. In 2012 we succeeded in expanding our position in
India in particular with the acquisition of two companies there," says
Uwe Röhrhoff, CEO of Gerresheimer AG.
In the 2012 financial year (December 1, 2011 to November 30, 2012),
Gerresheimer recorded substantial growth in revenues of 11.4%. Revenues
rose to EUR 1,219.1m. At constant exchange rates, revenues increased by
9.8%. In particular Gerresheimer achieved strong growth in the pharma
segment coupled with good revenue results in the cosmetic glass
business and the life science research segment.
Gerresheimer increased its operating result (adjusted EBITDA) by 8.8% to
EUR 236.5m in the 2012 financial year. The adjusted EBITDA margin
amounts to 19.4%, compared to the prior year's 19.9%. Net income rose
by 22.2% to EUR 66.5m. Earnings per share rose by 19.3% to EUR 1.92.
Adjusted earnings per share increased by 4.9% to EUR 2.56.
Gerresheimer invested EUR 118.9m in the 2012 financial year (up from EUR
86.2m in 2011). The company is expanding its production capacity for
so-called medical devices, i.e. products for drug delivery such as
prefilled glass syringes, insulin pens and asthma inhalers, in Germany,
Czech Republic and elsewhere. The Company is also focusing on growth in
the emerging markets. In April 2012 Gerresheimer acquired Neutral
Glass, one of India's leading manufacturers of pharmaceutical vials.
This was followed in December 2012 by the acquisition of the Indian
company Triveni, the regional market leader for plastic pharmaceutical
packaging and closures. Gerresheimer intends to achieve both organic
growth and growth through acquisitions in the future.
Gerresheimer is expecting growth in revenues at constant exchange rates
of five to six percent for the financial year 2013. The Company expects
an adjusted EBITDA margin on prior year level (2012: 19.4%). Due to the
good growth perspectives the investment volume of the financial year
2013 will be on the same level as the financial year just passed (2012:
"2012 was a good year for Gerresheimer AG. As in the past, we want our
shareholders to participate in the positive development of our
business," said Uwe Röhrhoff. The Management and Supervisory Boards
have agreed to propose a dividend of EUR 0.65 per share for the
financial year 2012 at the Annual General Meeting on April 18, 2013.
This represents a dividend ratio of 25% of adjusted net income. This
year's dividends are payable tax-free to shareholders resident in
Germany due to Gerresheimer AG's tax situation.
The online annual report is available at: http://annualreport2012.gerresheimer.com
SOURCE: Gerresheimer AG
For further information:
Director Corporate Communication & Marketing